IO Biotech Presents Groundbreaking Research at AACR-IO Conference
IO Biotech, a leading clinical-stage biopharmaceutical company, has unveiled exciting preclinical data regarding a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Factor Beta (TGF-?) in solid tumors. This presentation highlights the company's commitment to advancing its cancer vaccine pipeline and improving outcomes for patients suffering from various cancers.
Details of the Presentation
The significant findings were shared at the esteemed American Association for Cancer Research (AACR)-IO conference. The focus of the presented research centers around a peptide vaccine designed to induce T cell activation and enhance anti-tumor activity through modulation of the tumor microenvironment (TME).
Research Title and Highlights
The presentation, titled "A TGF-?-directed peptide vaccine induces T cell activation & drives anti-tumor activity by modulating the architecture of the tumor microenvironment," showcased the effectiveness of IO170. This investigational vaccine demonstrated promising results in reducing tumor growth in models of pancreatic adenocarcinoma and prostate cancer.
Presenter Insights
Dr. Matteo Bocci, Senior Scientist at IO Biotech, led the presentation. He emphasized the vaccine's ability to reshape the TME, fostering robust immune responses without causing systemic toxicity. The research points towards a new era in targeting immune-suppressive factors in cancer treatment.
Understanding TGF-?'s Role in Cancer
Transforming Growth Factor Beta (TGF-?) is a critical immune-suppressive factor found in the TME of numerous solid tumors, complicating the effectiveness of many immune-oncology therapies. Traditional approaches aimed at inhibiting TGF-? have often met with limited success due to the toxicity associated with systemic inhibition. IO Biotech’s strategy targets TGF-? activity specifically, enhancing the immune response while minimizing toxic side effects.
Future Directions for IO Biotech
The findings presented at the AACR-IO conference provide a strong rationale for further advancing the development of the TGF-?-targeted vaccine. Dr. Ayako Wakatsuki Pedersen, Senior Vice President of Translational Research at IO Biotech, expressed excitement about the potential clinical applications of this research. She stated that the approach uniquely addresses the immune resistance mechanisms in cancer by specifically targeting TGF?+ cells.
Investigational New Drug Application Plans
Looking ahead, IO Biotech is preparing for an Investigational New Drug Application (IND) submission to the FDA for IO170, anticipating a pivotal step towards advancing clinical trials and eventually helping patients with solid tumors.
About IO Biotech
IO Biotech is dedicated to developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines using their proprietary T-win platform. This innovative approach is designed to activate T cells to specifically target both tumor cells and immune-suppressive cells in the TME. Their lead investigational candidate, Cylembio™ (also known as IO102-IO103), has already shown promise in clinical trials, especially in conjunction with Merck’s anti-PD-1 therapy, KEYTRUDA.
Contact Information
For any inquiries or further information about their research and developments, you can contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
julie.funesti@edelman.com
Frequently Asked Questions
What are the main findings from IO Biotech's recent presentation?
The findings highlight the effectiveness of IO170 in reducing tumor growth by targeting the suppressive effects of TGF-? in various cancer models.
Why is TGF-? important in cancer treatment?
TGF-? plays a significant role as an immune-suppressive factor in the tumor microenvironment, often limiting the effectiveness of cancer therapies.
What is the next step for IO Biotech regarding IO170?
The company is preparing to submit an Investigational New Drug Application (IND) to the FDA for IO170 to initiate clinical trials.
Who presented the research findings at the AACR-IO conference?
Dr. Matteo Bocci, Senior Scientist at IO Biotech, presented the findings during the conference.
How does IO Biotech's T-win platform work?
IO Biotech's T-win platform is designed to activate T cells and specifically target both tumor cells and immune-suppressing cells within the tumor microenvironment.
